the question, does a higher percentage of them show placebo responses when, for example, placebo is prescribed by a doctor, dispensed by a pharmacist, and so forth.

Specific studies to test that have not been done in this universe, but there is other evidence to suggest that the act of prescribing and the involvement of health professionals in the therapeutic setting do increase the probability that that response will occur.

We could supply the committee with studies to that effect.

Senator BAUCUS. If you would, please.[1]

My second general question has to do with the timing of your study. Will you give me some indication of your timetable, when you plan to complete the studies and make the studies known?

Commissioner KENNEDY. Well, this review will be completed within a few months I would say. There is a scheduled meeting of the Controlled Substances Advisory Committee on February 12 and 13 at which we will share with that advisory committee a number of the safety considerations and we will respond to the need to advise DEA on the petition to reschedule.

We will be continuing our review of the efficacy studies and should discuss those with another advisory committee later on in the spring.

I would estimate that 3 or 4 months would be required to complete what we have undertaken now.

Senator BAUCUS. Thank you.

Senator NELSON. Thank you, very much. We appreciate your taking the time to come and testify.

Commissioner KENNEDY. Thank you, Mr. Chairman.

Senator NELSON. Commissioner Kennedy's full statement will appear in the record at this point.

[The prepared statement and supplemental information of Commissioner Kennedy follows:]

---

[1] See studies submitted by the Food and Drug Administration following Commissioner Kennedy's prepared statement, page 16826.